Xconomy: On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data
Summary
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data (Page 2 of 3) comes with contamination risks.Very rare cases of dangerous eye infections have been reported from compounded bevacizumab, and that risk is one reason some ophthalmologists don’t prescribe the drug.Via email, Humana spokesperson Marina Renneke said that its coverage was “consistent” with American Academy of Ophthalmology treatment guidelines and “is aligned” with National Institutes of Health research comparing the different wet AMD drugs.As the New York Times and Washington Post have reported, Medicare reimbursement rules allow eye doctors to gain more financially by buying one of the on-label treatments rather than bevacizumab.Clark of the Palmetto Center in South Carolina acknowledges that he is a paid consultant to Genentech, Regeneron, and Bayer and has been an investigator in several pegpleranib trials.
Classifications
AskAI Classifications
LabelsLinked Companies
